| 2.41 -0.105 (-4.18%) | 04-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.96  |
1-year : | 4.78 |
| Resists | First : | 3.39 |
Second : | 4.09 |
| Pivot price | 3.02 |
|||
| Supports | First : | 2.25 |
Second : | 1.88 |
| MAs | MA(5) : | 2.71 |
MA(20) : | 3.13 |
| MA(100) : | 3.32  |
MA(250) : | 4.2 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 3.6 |
D(3) : | 9.7 |
| RSI | RSI(14): 28.2 |
|||
| 52-week | High : | 10.09 | Low : | 1.29 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ OMGA ] has closed above bottom band by 3.0%. Bollinger Bands are 1.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.71 - 2.73 | 2.73 - 2.75 |
| Low: | 2.46 - 2.49 | 2.49 - 2.51 |
| Close: | 2.48 - 2.53 | 2.53 - 2.56 |
Omega Therapeutics, Inc. operates as a development-stage biopharmaceutical company. Its OMEGA Epigenomic Programming platform is designed to coopt nature's operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation. The company is developing omega epigenomic controller (OEC) candidates to up-regulate the expression of HNF4a, a transcriptional master regulator as a potential way to restore liver-cell function in patients suffering from chronic liver diseases; to control the expression of genes that have been strongly linked to cell-growth inhibition in patients with diabetes and other conditions to restore the capacity for corneal regeneration; to down-regulate expression of the CXCL1, 2, 3, and IL-8 gene cluster; to control expression of genes implicated in patients with idiopathic pulmonary fibrosis to halt or reverse disease progression and improve disease outcomes; to down-regulate the expression of SFRP1, a protein that inhibits hair growth; and to treat non-small cell lung cancer and small cell lung cancer. It is also developing OTX-2002 to down-regulate c-Myc, an oncogene. The company was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Sun, 14 Apr 2024
Omega Therapeutics, Inc. (OMGA) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Movies UK
Fri, 05 Apr 2024
Omega Therapeutics Kicks Start Trading On NASDAQ - AOL
Wed, 03 Apr 2024
Omega Therapeutics (OMGA) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Sun, 31 Mar 2024
Omega Therapeutics And Novo Nordisk Collaboration: A Cautious 'Buy' (NASDAQ:OMGA) - Seeking Alpha
Thu, 28 Mar 2024
Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update - GlobeNewswire
Thu, 28 Mar 2024
Omega Therapeutics, Inc. (OMGA) Reports Q4 Loss, Tops Revenue Estimates - Zacks Investment Research
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 55 (M) |
| Held by Insiders | 2.136e+007 (%) |
| Held by Institutions | 1.9 (%) |
| Shares Short | 3,720 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -9.869e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 92.9 % |
| Return on Equity (ttm) | -35.8 % |
| Qtrly Rev. Growth | 3.09e+006 % |
| Gross Profit (p.s.) | 18.9 |
| Sales Per Share | -64.93 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -92 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.04 |
| Price to Cash Flow | 4.18 |
| Dividend | 0 |
| Forward Dividend | 4.04e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|